Gå til innholdet
Global sound
Beyond Longevity

Beyond Longevity

Longevity Breakthrough or Expensive Dead End? How Investors Decide, with LongeVC’s Sergey Jakimov

· 59 min · Sesong 1 Episode 41

Episodebeskrivelse

Billions are flowing into longevity and biotech, but how do investors tell a genuine breakthrough from an expensive scientific dead end? Sergey Jakimov, founding and managing partner of LongeVC, joins Daphna Stern on Beyond Longevity to explain how investors decide which companies deserve backing. He says his team has reviewed almost 5,000 companies since 2021 and invested in only a tiny fraction.
Sergey shares the problems he sees again and again: overstated science, weak intellectual property and no credible route through clinical trials and regulatory approval. He also explains why some…

Nettsted: beyond-longevity.co.uk

Live, siste time: 12 938 låter på 6 279 stasjoner i 143 land

Oppdag verden gjennom radioen

Flere måter å oppdage på (9)

Hørt noe fint? Lagre det, eller åpne det rett i Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
RadiateFortsett å lytte